Ambreen Malik Uttra1*, Sakeena Noor1, Sumera Qasim2, Muhammad Talha Raheem3, Fakhria A. Al-Joufi2
1Department of Pharmacology, College of Pharmacy, University of
Sargodha, Sargodha, Pakistan
2Department of Pharmacology, College of Pharmacy, Jouf University,
72341 Aljouf, Saudi Arabia
3Department of Electrical and Computer Engineering, COMSATS
University Islamabad, Lahore Campus, Pakistan
*For Correspondence
ambreen.malik@uos.edu.pk
Non-alcoholic fatty liver disease
(NAFLD) is one of the most common chronic liver conditions worldwide, and its
incidence is still rapidly increasing. Nonetheless, there are still few
effective treatments available for this liver condition. It has been established
that NAFLD and mitochondrial dysfunction are closely related. Reactive oxygen
species (ROS) are produced when mitochondrial damage occurs, and oxidative
stress can exacerbate hepatic lipid buildup, inflammation, and fibrosis—all of
which are factors in development and pathophysiology of nonalcoholic fatty
liver disease (NAFLD). Consequently, pharmaceutical treatments that
specifically target mitochondria may offer a viable means of intervening in
NAFLD. Natural compounds that target mitochondria have been the subject of much
research recently, and their pharmacological action appears promising. By
summarizing the latest research on the therapeutic effects of compounds derived
from natural products that target mitochondria and fight the disease, this
chapter aimed to provide new therapeutic lead compounds and a point of
reference for the innovative drug development and clinical treatment of
nonalcoholic fatty liver disease (NAFLD).
Keywords
Non-alcoholic Fatty Liver, Mitochondrial Dysfunction, Insulin Resistance, Natural Compounds, Lipogenesis
Download PDF